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Abstract  
Objective: To examine the shape of the association between high density lipoprotein 
cholesterol (HDL-C) and mortality in a large general population sample. 
Approach and results: Adult participants (n=37,059, age= 57.7±11.9 years, 46.8% men) 
were recruited from general population household-based surveys (Health Survey for 
England and Scottish Health Survey). Individual participant data were linked with the British 
National Health Service Central Registry to record mortality. There were 2,250 deaths from 
all causes during 326,016 person-years of follow-up. When compared to the reference 
category (HDL-C = 1.5 – 1.99 mmol·L-1) a U-shaped association was apparent for all-cause 
mortality, with elevated risk in participants with the lowest (Hazard ratio=1.23, 95% CI, 1.06, 
1.44) and highest (1.25; 0.97, 1.62) HDL-C concentration. Associations for cardiovascular 
disease were linear, and elevated risk was observed in those with the lowest HDL-C 
concentration (1.49; 1.15, 1.94). 
Conclusions: A U-shaped association was observed between HDL-C and mortality in a 
large general population sample. 
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Abbreviations  
High-density lipoprotein cholesterol (HDL-C) 
Low-density lipoprotein cholesterol (LDL-C) 
Cardiovascular disease (CVD) 
Cholesteryl ester transfer protein (CETP) 
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Introduction  
Data from early prospective cohort studies suggest that there is an inverse and linear 
association between high-density lipoprotein cholesterol (HDL-C) and mortality.1 
Indeed, data from 15,252 white men and women in the Framingham Heart Study, the 
Lipid Research Clinics Prevalence Mortality Follow-up Study, the Lipid Research 
Clinics Coronary Primary Prevention Trial, and the Multiple Risk Factor Intervention 
Trial suggest that every 0.026 mmol·L-1 increase in HDL-C concentration reduces 
coronary heart disease risk by 2-3 % and cardiovascular disease (CVD) mortality risk 
by 3.7-4.7 %.1 Data from more recent prospective cohort studies suggest that the 
association between HDL-C and mortality is not linear over the entire range of HDL-
C concentrations.2-4 For example, analyses from the Copenhagen City Heart Study 
and the Copenhagen General Population Study suggest that the association 
between HDL-C and mortality is U-shaped, with both extreme high and low 
concentrations being associated with elevated all-cause mortality risk.4 Only one of 
the recent prospective cohort studies, however, was population-based;4 the other 
two were based on outpatients2 and kidney disease patients.3 Therefore, the 
objective of this study was to investigate the postulated U-shaped association 
between HDL-C concentration and mortality in a pooled analysis of a large general 
population sample.  
 
Materials and Methods 
Materials and Methods are available in the online-only Data Supplement. 
 
Results  
The sample comprised 37,059 participants (57.7±11.9 years, 46.8% men). Highly 
elevated levels of HDL-C (≥2.5 mmol·L-1) were identified in 2% of the cohort, and this 
group contained a higher proportion of women (Table 1). There were few differences 
in clinical characteristics between normal and highly elevated HDL-C, except for 
raised systolic blood pressure in the very high HDL-C group (Table 1). Participants in 
the very low HDL-C group (<1 mmol·L-1) generally displayed more risk factors, 
including a greater prevalence of smoking, physical inactivity, elevated body mass 
index and systolic blood pressure (Table 1). 
There were 2,250 deaths from all causes during 326,016 person-years of follow-up. 
When compared to the reference category (1.5 – 1.99 mmol·L-1) a U-shaped 
association was apparent (Table 2; Figure 1) for all-cause mortality, with elevated 
risk in the lowest and highest HDL-C categories. There were 649 deaths attributed to 
CVD although there was no evidence of a curvilinear trend. Compared with the 
reference category there was an increased risk of CVD only in the lowest HDL-C 
category (Table 2).  
We conducted a series of sensitivity analyses. The pattern of results remained 
largely similar when men and women were analyzed separately, albeit effect 
estimates were more robust in women (Supplemental Table I). We removed 
participants with existing CVD at baseline (3.6% of the sample reported a physician 
diagnosis of heart attack, stroke, or angina), although results were not changed 
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(Supplemental Table II). In a sub-sample from the Scottish surveys (n=10,047) we 
retrieved hospital admissions records and examined fatal and non-fatal CVD events 
(Supplemental Table III).  There were 545 coronary heart disease events and 231 
stroke events; compared with the reference category there was an increased risk 
only in the lower HDL-C categories (Supplemental Table III) that mirrored the results 
for CVD mortality presented in the main analyses. We explored if the U-shaped 
association with all-cause mortality was being driven by cancer, although no clear 
associations emerged (Supplemental Table IV). 
 
Discussion 
The aim of this study was to re-examine recent paradoxical findings from a regional 
cohort of Danish adults that suggested a U-shaped association between HDL-C and 
mortality.4 In our pooled (nationwide) British cohort we partially replicated the 
curvilinear association for all-cause mortality, but not for CVD.  
It was thought that there was an inverse and linear relationship between HDL-C 
concentration and CVD mortality.1 Indeed, a HDL-C concentration of ≥1.55 mmol·L-1 
was regarded as a ‘negative’ risk factor and its presence removed one risk factor 
from the total count used for setting treatment goals for low-density lipoprotein 
cholesterol (LDL-C) concentration.5 However, recent prospective cohort studies 
suggest that the association between HDL-C concentration and mortality is U-
shaped.2-4 It has been suggested that the contradictory findings of early and recent 
prospective cohorts studies may be explained by the fact that few individuals have 
extremely high HDL-C concentrations and are often grouped together with 
individuals with only modestly high concentrations.4 This would seem to be the case. 
In early studies, low HDL-C was defined as <1.04 mmol·L-1, medium as 1.04-1.30 
mmol·L-1, and high as ≥1.30 mmol·L-1; And, a linear relationship between HDL-C 
concentration and CVD mortality was observed.1 In recent studies, reference groups 
were defined as 1.06-1.29 mmol·L-1 in men and 1.32-1.55 mmol·L-1 in women 
(“based on previous studies”),2 1.06 mmol·L-1 in men and women (the median value 
in the cohort),3 and 1.55-1.99 mmol·L-1 in men and 2.0-2.49 mmol·L-1 in women (the 
HDL-C concentrations associated with lowest mortality);4 And, U-shaped 
relationships between HDL-C concentration and CVD mortality2 and all-cause 
mortality2-4 were observed. There was relatively low statistical power in the early 
prospective cohort studies (only 584 deaths).1 There were 17,952 deaths,2 541,682 
deaths,3 and 10,678 deaths4 and relatively high statistical power in recent 
prospective cohort studies.  
 
The mechanisms remain unclear although it is possible that in participants with 
highly elevated HDL-C there may be disparity between concentration and function as 
HDLs have several well documented cardio-protective properties.6 That we found no 
evidence of a U-shaped association for CVD mortality is in contrast with some recent 
data.4 Nevertheless, when examining secondary endpoints, including ischaemic 
heart disease, myocardial infarction, and ischaemic stroke events, they found no 
significant increase in risk with highly elevated HDL-C concentrations.4 In our 
sensitivity analyses we explored if the U-shaped association with all-cause mortality 
was being driven by cancer deaths, although no clear patterns emerged 
6 
 
(Supplemental Table IV). Nevertheless, there were insufficient events to undertake 
detailed analyses of cancer sub-types, nor were we adequately powered to explore 
other death causes, for example, related to infection. 
Clinicians should be aware that adults with extremely high HDL-C concentrations 
may be a high-risk group for all-cause mortality. Drugs that are currently prescribed 
to clinically manage lipid levels do not directly target HDL-C. The inhibition of 
cholesteryl ester transfer protein (CETP) or addition of niacin to statin therapy can 
produce substantial increases in HDL-C levels, in addition to reductions in LDL-C. 
However, some clinical trials using CETP inhibitors have been controversial7-9 and 
other trials testing different types of CETP inhibitor10 or niacin11-12 either did not 
reduce CVD risk or the effects were attributed to reduction in LDL-C. In addition, 
recent observational data using CETP gene variants as an instrumental variable has 
also questioned the causal role of HDL-C in the etiology of CVD.13 It is, however, 
plausible that there is a disparity between concentration and function in those with 
extremely high HDL-C concentrations.6 
These data are observational thus we cannot infer causality. We cannot discount the 
possibility of reverse causation; however, in keeping with previous analyses in the 
same cohort,14,15 we excluded deaths in the first 24 months of follow-up, we adjusted 
for longstanding illness, and showed that removal of participants with existing CVD 
did not influence the results. The covariates were selected a priori based on lifestyle 
and clinical factors known to influence HDL-C, although we cannot discount residual 
confounding. For example, in the absence of data on triglyceride and LDL-C levels 
we were only able to adjust for total cholesterol. 
In conclusion, the present population-based study is important because it confirms 
the results of the only other such study.4 The available evidence suggests that there 
is a U-shaped association between HDL-C concentration and all-cause mortality in 
white men and women. More research is required to determine the association 
between HDL-C concentration and mortality in other groups.  
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Highlights  
 HDL cholesterol is generally believed to be inversely associated with risk of disease. 
 We observed a U-shaped association between HDL cholesterol and mortality in a 
large population sample. 
 There was a linear inverse association between HDL-C and cardiovascular disease. 
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Figure caption 
Figure 1. The association between high density lipoprotein-cholesterol and all-cause 
mortality.  
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Table 1. Baseline characteristics of the sample 
Variable High density lipoprotein-cholesterol category (mmol·L-1) 
<1.0  1.0 – 1.49 1.5 – 1.99 2.0 – 2.49 ≥2.5 
Age (mean±SD) 45.7±15.8 45.5±16.3 46.9±16.1 49.6±15.8 52.7±14.7 
Men (%) 73.4 56.8 33.1 19.2 17.3 
Smokers (%) 31.9 25.9 20.6 17.6 19.0 
Regular alcohol (at 
least 5/wk) (%) 
9.6 13.9 19.3 25.9 39.8 
Meets physical 
activity guideline 
(%) 
23.5 28.1 31.3 33.1 29.7 
Longstanding 
illness (%) 
47.9 42.4 39.2 39.6 45.4 
Total cholesterol 
(mmol.L-1) 
5.4±1.2 5.5±1.2 5.6±1.1 5.9±1.1 6.3±1.1 
Systolic blood 
pressure (mmHg) 
133.1±17.6 129.9±17.8 128.7±18.9 129.2±19.6 132.2±20.3 
Body mass index 
(Kg.m-2 ) 
28.7±4.7 27.4±4.8 25.9±4.4 24.9±3.9 24.2±3.8 
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Table 2. Association between high density lipoprotein-cholesterol and mortality (n=37,059) 
HDL-C 
category 
(mmol·L-1) 
N All 
deaths 
Hazard Ratio (95% CI) 
All cause mortality 
CVD 
deaths 
Hazard Ratio (95% CI) 
CVD mortality 
 
<1.0 2723 254 1.23 (1.06, 1.44) 95 1.49 (1.15, 1.94) 
1.0 - 1.49 16,885 1035 1.09 (0.98, 1.20) 297 1.03 (0.85, 1.24) 
1.5 – 1.99 13,070 664 1.00 (Ref) 195 1.00 (Ref) 
2.0 – 2.49 3,637 233 1.18 (1.02, 1.38) 51 0.89 (0.65, 1.21) 
≥2.5  744 64 1.25 (0.97, 1.62) 11 0.76 (0.41, 1.40) 
P-curvilinear 
trend 
  0.003  0.18 
 
Models adjusted for: age, sex, smoking (never; ex-smoker; <10/d cigarettes, 10-19/d, ≥20/d), 
frequency of alcohol intake (5 or more per week; 1 – 4 per week; 1 – 2 per month; once 
every few months; ex-drinker; never), moderate to vigorous physical activity (none, 1 – 149 
min/week; ≥150 min/wk), longstanding illness, total cholesterol, systolic blood pressure, body 
mass index. 
 
